Indexed in

External link

License and use

Citations

Altmetrics

Analysis of institutional authors

Loscertales, JavierAuthor

Share

Hairy cell leukemia treated initially with purine analogs: a retrospective study of 107 patients from the Spanish Cooperative Group on Chronic Lymphocytic Leukemia (GELLC)

Publicated to:LEUKEMIA & LYMPHOMA. 55 (5): 1007-1012 - 2014-05-01 55(5), DOI: 10.3109/10428194.2013.827187

Authors: Lopez Rubio, Montserrat; Da Silva, Carolina; Loscertales, Javier; Seri, Cristina; Baltasar, Patricia; Colado, Enrique; Perez Fernandez, Inmaculada; Osma, Mar; Gomis, Federico; Gonzalez, Marcos; Jarque, Isidro; Vargas, Manuel; Monzo, Encarnacion; Monteagudo, Dolores; Isabel Orts, Maria; Pardal, Emilia; Carbonell, Felix; Perez Calvo, Cesar; Garcia-Marco, Jose A

Affiliations

Abstract

Purine analogs are highly effective in hairy cell leukemia (HCL) with response rates of 85%, but with many late relapses. We have retrospectively reviewed the clinical data from 107 patients treated with pentostatin (n = 27) or cladribine (n = 80), to investigate the long-term efficacy and to identify factors associated with the treatment-free interval (TFI). Complete remission and minimal residual disease (MRD) rates were similar in both groups. Median TFI was shorter (95 vs. 144 months) in the pentostatin group, although the difference was not significant (p = 0.476). MRD+ patients had shorter TFI than MRD - patients (97 months vs. not reached, p < 0.049). A hemoglobin level < 10 g/dL predicted for a shorter TFI only in the pentostatin group. Quality of response and number of hairy cells in the bone marrow are independent risk factors of treatment failure. The relationship between MRD+ and shorter TFI makes it of special interest to explore consolidation therapy with monoclonal antibodies to achieve durable responses.

Keywords